The present data article aims to describe the input parameters for a Markov model assessing the cost-effectiveness of four treatment sequences for patients with HER-2 positive metastatic breast cancer. The model input parameters include costs for physician visits, drugs, adverse event management, computed tomography (CT) scan, laboratory tests, echocardiogram, utilities, disutilities as well as the shape and scale parameters of a log-logistic distribution used for the transition probabilities.
Data
The dataset includes the model input parameters for a Markov model assessing the costeffectiveness of four trastuzumab containing sequences for HER-2 positive metastatic breast cancer patients as well as a brief description of the model assumptions. These input parameters include cost, transition probabilities, and utilities. Cost data include physician visit fee (Table 1) , treatment acquisition cost both considering or not considering drug wastage (Table 2) , costs associated with adverse event management (Tables 2 and 3) , costs for computed tomography (CT) scan and echocardiogram and laboratory costs (Table 4) . For transition probabilities, the shape and scale parameters for progression-free survival and overall survival were estimated as well as the probability of developing adverse events while on different treatment regimens. The entire list of model input parameters including the lower and higher bounds for deterministic sensitivity analysis as well as the distribution and standard deviations for probabilistic sensitivity analyses are shown in Tables 5 and 6 for base case and no drug wastage scenarios respectively.
Experimental design, materials, and methods
All costs presented were direct medical costs from the perspective of the Taiwanese National Health Insurance Administration (TNHIA). Cost for physician visits, treatments, CT scans, and laboratory tests were obtained from the website of TNHIA and personal communication. Most HER-2 targeted treatments are dosed based on weight or body surface area (BSA), so the treatment costs were then calculated based on the average height and weight for the Taiwanese female population. The average height and weight were obtained from the Ministry of Health and Welfare, Department of Statistics in Taiwan. Two cost strategies were developeddwith drug wastage and without drug wastage. In the drug wastage scenario, the price per vial for each intravenous drug was not broken down. For example, the calculated dosage for docetaxel is 119.25 mg, the total costs for 1 vial of 80mg plus the cost for 2 vials of 20 mg which equals to 120 mg will represent the costs for 119.25. mg docetaxel. However, in the no drug wastage scenario, the price per vial for each intravenous drug was broken down. For example, the calculated dosage for docetaxel is 119.25 mg and the costs for Specifications Table   Subject Economics and Econometrics Specific subject area Cost-effectiveness analysis  Type of data  Tables  How data were acquired  Data were obtained from Value of the Data Our data provide input parameters for cost, utilities and transition probabilities for cost-effectiveness analysis (CEA) of Trastuzumab-based regimens for metastatic breast cancer patients in Taiwan.
Researchers conducting economic evaluation including cost-effectiveness analysis and cost of illness studies for metastatic breast cancer patients would benefit from these data. Parenteral drug costs provided in this article are adjusted for wastage through a scenario analysis. Transition probabilities for progression and mortality were obtained from published clinical trials. Individual patient data (IPD) were obtained from the PFS and OS Kaplan-Meier curves from these clinical trials using a method described previously. Five standard parametric distributions were fitted to the IPD: exponential, Weibull, Gompertz, lognormal, and log-logistic. The log-logistic model was then selected and used to reconstructed IPD and derived equations for transition probabilities using the shape and scale parameters of the fitted model because it had the greatest model fit which was evaluated based on AIC and BIC. Utilities were obtained from published literature and clinical trials. gov/data/inflation_calculator.htm); Anorexia and headache were excluded based on clinical expert opinion; -: Adverse events occurred in less than 5% of patients. 
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